ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2361

Misdiagnosis of Giant Cell Arteritis Presenting As Fever of Unknown Origin

Chiara Stagnaro1, Rosaria Talarico2, Claudia Ferrari2, Anna d'Ascanio3 and Stefano Bombardieri4, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2University of Pisa, Rheumatology Unit, Pisa, Italy, 3Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, 4Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Diagnosis and giant cell arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Giant cell arteritis (GCA) represents the most common primary vasculitis of the elderly, that usually involves large and medium sized arteries. The wide spectrum of clinical manifestations can extensively vary, from cranial symptoms, such as headache, jaw claudication or visual alterations, to constitutional symptoms, like fever, weight loss or asthenia. Fever of unknown origin (FUO) may sometimes represent the initial symptom of GCA and when it is not associated with other typical GCA features, unfortunately the diagnosis can be delayed. The primary aim of this study was to evaluate the prevalence of GCA presenting as FUO. The secondary aims were: to identify delays in recognizing patients with GCA presenting as FUO and to explore any potential differences between the subset of GCA patients characterised by the presence of FUO at the onset, and the other patients of the cohort.

Methods: Epidemiological and clinical data of 180 GCA patients followed in the last 15 years in our Unit were analysed. We quantified the latency period between the onset of signs and symptoms and the final diagnosis of GCA in terms of months.

Results: One hundred and thirty-five patients (13 males and 122 females, mean ± SD age at the onset 75±6 years, mean follow-up 8 years) had shown at the onset signs and symptoms suggestive of GCA (new onset headache and/or scalp pain 78%, jaw claudication 36%, vision loss 33%, abnormal temporal artery on examination 32%, dizziness 29%) while 45 patients (9 males and 36 females, mean age at the onset 67±2 years, mean follow-up 6 years) were sent to our attention because of FUO onset and an increase of erythrocyte sedimentation rate and C-reactive protein not otherwise justified. After an extensive work-up aimed at excluding any kind of infection, malignancy or hematological disorder, we performed temporal artery biopsy (TAB) in all patients presenting as FUO, that resulted positive in 52% of cases. Moreover, (18)F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) was performed in 29 cases and was positive in 27. The main PET alterations reported were characterized by a (18)FDG uptake of the aortic arch and its major branches, including the carotid, subclavian, thoracic aorta and, less frequently, the abdominal aorta. The mean latency period between the onset of FUO and the diagnosis of GCA was 7±2 months, which was significantly higher compared with the mean latency period between the onset of signs and symptoms suggestive of GCA and the definitive diagnosis (3±1 months) in the other patients of the cohort. No difference was noted between the 2 groups, except for the mean age at the onset, which seems to be earlier in GCA patients presenting with FUO.

Conclusion: GCA patients presenting with constitutional symptoms may sometimes represents a diagnostic challenge and our results confirm that FUO must to be carefully investigated in elderly patients. In fact, there are major delays in the recognition of GCA patients presenting with FUO, and it partially seems to be due to the long diagnostic work-up before performing a rheumatologic evaluation.


Disclosure:

C. Stagnaro,
None;

R. Talarico,
None;

C. Ferrari,
None;

A. d’Ascanio,
None;

S. Bombardieri,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/misdiagnosis-of-giant-cell-arteritis-presenting-as-fever-of-unknown-origin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology